X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AJANTA PHARMA with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AJANTA PHARMA   MYLAN
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
MYLAN
Dec-14
AJANTA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,8184,285-   
Low Rs1,1063,019-   
Sales per share (Unadj.) Rs239.51,466.8-  
Earnings per share (Unadj.) Rs52.8176.7-  
Cash flow per share (Unadj.) Rs59.5284.4-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs230.0729.1-  
Shares outstanding (eoy) m88.77378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x6.12.5 245.2%   
Avg P/E ratio x27.720.7 134.0%  
P/CF ratio (eoy) x24.612.8 191.4%  
Price / Book Value ratio x6.45.0 126.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m129,7821,381,812 9.4%   
No. of employees `0006.825.0 27.2%   
Total wages/salary Rs m3,7650-   
Avg. sales/employee Rs Th3,128.422,199.6 14.1%   
Avg. wages/employee Rs Th554.00-   
Avg. net profit/employee Rs Th689.72,674.3 25.8%   
INCOME DATA
Net Sales Rs m21,258554,991 3.8%  
Other income Rs m242-3,235 -7.5%   
Total revenues Rs m21,499551,756 3.9%   
Gross profit Rs m6,584138,029 4.8%  
Depreciation Rs m59640,762 1.5%   
Interest Rs m423,939 0.0%   
Profit before tax Rs m6,22670,093 8.9%   
Minority Interest Rs m0-288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5392,947 52.2%   
Profit after tax Rs m4,68666,858 7.0%  
Gross profit margin %31.024.9 124.5%  
Effective tax rate %24.74.2 587.9%   
Net profit margin %22.012.0 183.0%  
BALANCE SHEET DATA
Current assets Rs m12,236487,910 2.5%   
Current liabilities Rs m3,461381,448 0.9%   
Net working cap to sales %41.319.2 215.2%  
Current ratio x3.51.3 276.4%  
Inventory Days Days6078 77.1%  
Debtors Days Days84107 78.8%  
Net fixed assets Rs m11,140128,396 8.7%   
Share capital Rs m17719,626 0.9%   
"Free" reserves Rs m20,2370-   
Net worth Rs m20,414275,885 7.4%   
Long term debt Rs m10412,145 0.0%   
Total assets Rs m24,4861,111,240 2.2%  
Interest coverage x1,519.43.9 38,682.3%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.90.5 173.8%   
Return on assets %19.28.2 234.4%  
Return on equity %23.024.2 94.7%  
Return on capital %30.513.6 223.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,0520-   
CASH FLOW
From Operations Rs m2,85472,954 3.9%  
From Investments Rs m-2,604-57,534 4.5%  
From Financial Activity Rs m-2-19,223 0.0%  
Net Cashflow Rs m248-3,803 -6.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.89 Rs / USD

Compare AJANTA PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare AJANTA PHARMA With: TTK HEALTHCARE  STRIDES PHARMA SCIENCE  ABBOTT INDIA  STERLING BIOTECH  WYETH LTD  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views On News

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 16, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS